GlassScriptPhysician profile
Hans C Andersson
NPI 1801987664
$37,315.47
in general payments reported to CMS, 2019-2025
6 companies · $4,189 in 2025
The $4,189 reported for 2025 was more than what 76% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,890 · 2021: $2,692 · 2022: $494 · 2023: $13K · 2024: $3,171 · 2025: $4,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $7,073 · Travel and Lodging: $2,206 · Food and Beverage: $744 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,200.00 |
| Consulting Fee | $7,073.40 |
| Travel and Lodging | $2,205.64 |
| Food and Beverage | $744.29 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $28,669.16 | 2019-2025 | Palynziq, Voxzogo 1.2mg |
| Genzyme Corporation | $6,627.67 | 2019 | |
| Bioverativ Therapeutics INC. | $1,890.00 | 2020 | |
| Spark Therapeutics, INC. | $59.93 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $48.79 | 2022-2023 | Dojolvi |
| Zevra Therapeutics INC | $19.92 | 2024 | Olpruva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Andersson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.